Related Experiment Video

Updated: Jul 11, 2026

An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

Gliptins: a new class of oral hypoglycaemic agent

H Chahal1, T A Chowdhury

  • 1Department of Diabetes and Metabolism, The Royal London Hospital, UK.

QJM : Monthly Journal of the Association of Physicians
|September 21, 2007
PubMed

Insights

New gliptin medications offer a promising approach to managing type 2 diabetes by enhancing incretin hormone action. These oral drugs inhibit dipeptidyl peptidase-IV (DPP-IV), showing potential for improved glucose control with minimal side effects.

Area of Science:

  • Endocrinology and Metabolism
  • Pharmacology

Background:

  • Type 2 diabetes is a growing global epidemic with treatment challenges.
  • Existing therapies often fail to fully achieve treatment goals.
  • Incretin hormones play a key role in glucose homeostasis.

Purpose of the Study:

  • To discuss a novel therapeutic approach for type 2 diabetes.
  • To focus on enhancing and prolonging the physiological actions of incretin hormones.
  • To review the mechanism of action, efficacy, and adverse effects of gliptins.

Main Methods:

  • Review of existing literature on incretin hormones and gliptins.
  • Discussion of dipeptidyl peptidase-IV (DPP-IV) inhibition.
  • Analysis of clinical data from regulatory licensing studies.

Main Results:

  • Gliptins inhibit DPP-IV, increasing incretin hormone levels.
  • These agents represent a new class of oral hypoglycaemic medication.
  • Published studies suggest gliptins are weight-neutral with few side effects.

Conclusions:

  • Gliptins offer a promising new oral treatment option for type 2 diabetes.
  • Further clinical studies are needed to fully understand long-term efficacy and safety.
  • Enhancing incretin action is a viable strategy for managing type 2 diabetes.

More Related Videos

Improving IV Insulin Administration in a Community Hospital12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Related Concept Videos

Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...